Adresse 1 Place Pierre Potier, 31106 Toulouse

Nombre d'employés 23

Site web

Téléphone 0531616069

Présentation de l'entreprise

GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.

GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in cancer.

The company develops low-fucose EMABling® antibodies with increased tumor cell killing properties through the activation of immune system cells. GamaMabs has a licensing agreement with MedImmune (USA) to develop an Antibody Drug Conjugate targeting cancer.” from